Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)

Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells

(2019) David Muench et al.   PLoS One

A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non–small-cell Lung Cancer

(2018) Fengying Wu et al.   Clinical Lung Cancer

Recent progress in systemic treatment for lung cancer

(2018) Jeffrey W. Clark et al.   CURRENT OPINION IN PULMONARY MEDICINE

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

(2018) Chia-Chi Lin et al.   Lancet Respiratory Medicine

Albendazole inhibits HIF-1α-dependent glycolysis and VEGF expression in non-small cell lung cancer cells

(2017) Fang Zhou et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Progress and prospects of early detection in lung cancer

(2017) Sean Blandin Knight et al.   Open Biology

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

(2017) Rafael Rosell et al.   Lancet Respiratory Medicine

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

(2014) Fairooz Kabbinavar et al.   Journal of Thoracic Oncology

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany

(2010) Joaquim Bosch-Barrera et al.   LUNG CANCER